CAROL RUBEO: Open Payments
NPI 1184484537 · GREENWICH, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,160 in 59 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $958 · 2025 $1,160
Food & beverage: $1,160
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $385 |
| Alkermes, Inc. | 9 | $137 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $55 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $52 |
| Biogen, Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
Products named: VRAYLAR, ARISTADA, REXULTI, CAPLYTA, ZURZUVAE, TRINTELLIX, COBENFY, FANAPT.
Industry payments across CT — which companies pay providers there.
